Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
Last trade$12.29
Day change-$0.42 (-3.30%)
Day range$12.16 – $13.05
Volume103,879
Market cap$174M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$174.45M
Price / earnings
—
Price / book
1.97×
Price / sales
135.03×
EV / sales
103.9×
EV / EBITDA
-1.84×
Profitability
Earnings per share
-$7.73
Return on assets
-71.65%
Return on equity
-120.09%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
7.3×
Quick ratio
7.3×
Cash ratio
2.69×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$63.87M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for KRRO, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$1.29M
$1.09M
$1.46M
$2.55M
$2.27M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$1.29M
$1.09M
$1.46M
$2.55M
$2.27M
Selling, general and administrative
$6.35M
$6.52M
$7.49M
$6.19M
$6.51M
$7.29M
$7.83M
$8.35M
Research and development
$12.1M
$13.59M
$12.95M
$10.99M
$13.82M
$20.14M
$19.74M
$16.96M
Total operating expenses
$18.46M
$20.11M
$20.44M
$51.69M
$20.33M
$28.66M
$27.57M
$25.31M
Operating income
-$18.46M
-$20.11M
-$20.44M
-$50.4M
-$19.24M
-$27.2M
-$25.02M
-$23.04M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$17.29M
-$18.81M
-$19.53M
-$49.41M
-$18.06M
-$25.77M
-$23.39M
-$21.1M
Income taxes
$260K
$108K
$95K
$636K
$0
$1K
$0
$103K
Net income
-$17.55M
-$18.92M
-$19.63M
-$50.04M
-$18.06M
-$25.77M
-$23.39M
-$21.2M
Net income attributable to common shareholders
-$17.55M
-$18.92M
-$19.63M
-$50.04M
-$18.06M
-$25.77M
-$23.39M
-$21.2M
EBITDA
-$18.1M
-$19.75M
-$20.06M
-$15.23M
-$18.06M
-$24.74M
-$23.8M
-$21.79M
Basic earnings per share
-$0.98
-$1.07
-$1.69
-$5.31
-$1.92
-$2.74
-$2.49
-$2.26
Diluted earnings per share
-$0.98
-$1.07
-$1.69
-$5.31
-$1.92
-$2.74
-$2.49
-$2.26
Recent news
Company coverage with links to the original publishers.
Korro Bio, a clinical-stage biopharmaceutical company developing genetic medicines using its OPERA platform for RNA editing, announced that CEO Ram Aiyar will present at the Jefferies Global Healthcare Conference in London on November 19, 2026. The company is advancing its portfolio including KRRO-121 in Phase 1/2 trials and KRRO-111 for alpha-1 antitrypsin deficiency treatment.
MediWound (MDWD) shares rose 6.1% following strong commercial performance of its NexoBrid therapy for burn treatment, with record quarterly revenue and growing hospital adoption. The company expects quarterly losses of $0.66 per share but projects 40.4% revenue growth. However, unchanged earnings estimates suggest caution about sustained momentum.
Korro Bio (KRRO) shares jumped 29.7% following announcement of encouraging preclinical results for KRRO-111, an RNA-editing therapy for alpha-1 antitrypsin deficiency. The candidate showed strong activity in restoring functional protein while reducing harmful protein in the liver. However, earnings estimate revisions remain unchanged, which may limit sustained upward momentum. The stock carries a Zacks Rank #3 (Hold).
Korro Bio announced that CEO Ram Aiyar will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The biopharmaceutical company is focused on developing RNA editing genetic medicines for rare and prevalent diseases. A live webcast will be available on their investor relations website.
Korro Bio, a clinical-stage biopharmaceutical company, announced that the FDA has granted orphan drug designation to its investigational medicine KRRO-110 for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). KRRO-110 is currently being evaluated in a Phase 1/2a clinical study, and the company expects to report interim data in the second half of 2025.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.